The 1 analysts offering 12-month price forecasts for Celyad Oncology SA have a median target of 2.72, with a high estimate of 2.72 and a low estimate of 2.72. The median estimate represents a +171.93% increase from the last price of 1.00.
The current consensus among 2 polled investment analysts is to Hold stock in Celyad Oncology SA. This rating has held steady since October, when it was downgraded from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.27
Reporting Date Aug 05
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.